Cell Press selected to publish Molecular Therapy family of journals

October 28, 2016

Molecular Therapy, the official journal of The American Society of Gene and Cell Therapy (ASGCT), has a new home at Cell Press, a leading publisher of biomedical and chemical research and reviews. This exciting new publishing partnership, to begin in January 2017, will see Cell Press produce and distribute ASGCT's four journals, which include its flagship title along with open-access options Molecular Therapy -- Methods & Clinical Development, Molecular Therapy -- Nucleic Acids, and Molecular Therapy -- Oncolytics.

"We are delighted for this premier collection of journals in the exciting areas of genetic and cellular therapeutics to join the Cell Press family as a society partnership reflecting our shared interest in the translation of basic science into therapeutic advance," says CEO Dr. Emilie Marcus.

ASGCT (@ASGCTherapy), established in 1996, is a non-profit organization based in Milwaukee, Wisconsin that represents the largest community of basic researchers and clinicians devoted to the discovery of gene and cell therapies in the United States and worldwide. The Society launched Molecular Therapy in 2000, which has since become the most cited journal in gene therapy, and has expanded its offerings to the scientific community with new journal launches and special issues.

"ASGCT is excited to bring the Molecular Therapy family of journals to Cell Press," says President Dr. Cindy Dunbar. "This new relationship between the ASGCT and Cell Press should improve the dissemination of research breakthroughs in gene and cell therapies, thus enhancing our mission of using these therapies to alleviate human disease."

"The expertise of Cell Press and its reputation of excellent, world-leading quality couples well with Molecular Therapy's position as the leading international source for original research in gene and cell therapies," says Molecular Therapy Editor-in-Chief Dr. Seppo Yla-Herttuala. "These collective efforts will serve as the vehicle driving new science as it transforms the practice of medicine to the benefit of patients and society."

With the addition of ASGCT, Cell Press now publishes a total of 38 journals, including the flagship Cell, Neuron, Current Biology, and most recently Chem. Other selected society partners include: The American Society of Human Genetics (AJHG); the Biophysical Society (Biophysical Journal); the International Society for Stem Cell Research (Stem Cell Reports), and the Institute of Plant Physiology and Ecology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and Chinese Society of Plant Biology (Molecular Plant).
About the Molecular Therapy Collection:

Molecular Therapy (@MolTherapy) is a monthly journal for international research on the development of molecular and cellular therapeutics to correct genetic and acquired diseases, including but not limited to research on gene transfer and editing, vector development and design, stem cell manipulation, vaccine development, pre-clinical target validation, safety/efficacy studies, and clinical trials. Editor-in-Chief: Seppo Ylä-Herttuala, University of Eastern Finland.

Molecular Therapy -- Methods & Clinical Development is a monthly, open-access journal publishing new methods and significant improvements to established research techniques in basic, translational, and clinical cell and gene therapy. Editor-in-Chief: Roland W. Herzog, University of Florida.

Molecular Therapy -- Nucleic Acids publishes open-access research each month targeted to the advances in nucleic acid-based therapeutics to treat and/or correct genetic and acquired disease. Editor-in-Chief: John Rossi, Beckman Research Institute of the City of Hope.

Molecular Therapy -- Oncolytics is a monthly, open-access journal focusing on the development and clinical testing of viral, cellular, and other biological therapies targeting cancer. Editor-in-Chief: Yuman Fong, Beckman Research Institute of the City of Hope.

For table of content alerts, please sign up at http://www.cell.com/molecular-therapy-family/home.

Learn more about ASGCT at http://www.asgct.org/.

Cell Press (@CellPressNews), an imprint of Elsevier, is a leading publisher of scientific research and reviews. We drive science forward and promote cross-pollination of ideas with our passion for excellence and commitment to innovation. Our aim is to engage the scientific community by communicating important, exciting discoveries made today that will impact the future of research. Visit http://www.cell.com/. To receive Cell Press media alerts, contact press@cell.com.

Cell Press

Related Gene Therapy Articles from Brightsurf:

Risk of AAV mobilization in gene therapy
New data highlight safety concerns for the replication of recombinant adeno-associated viral (rAAV) vectors commonly used in gene therapy.

Discovery challenges the foundations of gene therapy
An article published today in Science Translational Medicine by scientists from Children's Medical Research Institute has challenged one of the foundations of the gene therapy field and will help to improve strategies for treating serious genetic disorders of the liver.

Gene therapy: Novel targets come into view
Retinitis pigmentosa is the most prevalent form of congenital blindness.

Gene therapy targets inner retina to combat blindness
Batten disease is a group of fatal, inherited lysosomal storage disorders that predominantly affect children.

New Human Gene Therapy editorial: Concern following gene therapy adverse events
Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM).

Restoring vision by gene therapy
Latest scientific findings give hope for people with incurable retinal degeneration.

Gene therapy/gene editing combo could offer hope for some genetic disorders
A hybrid approach that combines elements of gene therapy with gene editing converted an experimental model of a rare genetic disease into a milder form, significantly enhancing survival, shows a multi-institutional study led by the University of Pennsylvania and Children's National Hospital in Washington, D.C.

New technology allows control of gene therapy doses
Scientists at Scripps Research in Jupiter have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing.

Gene therapy: Development of new DNA transporters
Scientists at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed new delivery vehicles for future gene therapies.

Gene therapy promotes nerve regeneration
Researchers from the Netherlands Institute for Neuroscience and the Leiden University Medical Center have shown that treatment using gene therapy leads to a faster recovery after nerve damage.

Read More: Gene Therapy News and Gene Therapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.